![The Weekly Break Out Ep. 22: How the US hit Iran, and spooky space moves [Video]](https://breakingdefense.com/wp-content/uploads/sites/3/2025/06/250622_b2_takeoff_USAF-scaled-e1750776866152.jpg?#)
Royalty signs off on $2B to bankroll Revolution's RAS cancer drug's road to regulators
Revolution Medicines has secured a potential funding infusion of up to $2 billion from Royalty Pharma in return for a slice of the profits if Revolution’s lead cancer drug makes it to market.
Revolution Medicines has secured a potential funding infusion of up to $2 billion from Royalty Pharma in return for a slice of the profits if Revolution’s lead cancer drug makes it to market.
